Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aldeyra Therapeutics, Inc.ALDX · Entity 6839 | Chief Financial Officer | March 06, 2018 | March 08, 2018 |
| Stoke Therapeutics, Inc.STOK · Entity 1723 | Former CFO | March 27, 2024 | June 07, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aldeyra Therapeutics, Inc.
Report date March 06, 2018 · Filed March 08, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 8,563 |
Ending reported balance
After 2017-12-29 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2017-06-30 · Grant · Acquired 2,077 · Balance 5,410 F1: Represents the voluntary reporting of 2,077 shares of common stock acquired under the Issuer's Employee Stock Purchase Plan (ESPP) in June 2017. F2: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on June 30, 2017. Row 2 · 2017-12-29 · Grant · Acquired 3,153 · Balance 8,563 F3: Represents the voluntary reporting of 3,153 shares of common stock acquired under the Issuer's ESPP in December 2017. F4: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on July 3, 2017. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.60 · Expires 2028-03-05 | Direct | 125,670 |
Reported balance
After 2018-03-06 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-03-06 · Grant · Acquired 125,670 · Balance 125,670 F5: The shares subject to this option shall vest in equal monthly installments over the next 48 months of continuous service to the Issuer after January 1, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the voluntary reporting of 2,077 shares of common stock acquired under the Issuer's Employee Stock Purchase Plan (ESPP) in June 2017.
F2: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on June 30, 2017.
F3: Represents the voluntary reporting of 3,153 shares of common stock acquired under the Issuer's ESPP in December 2017.
F4: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on July 3, 2017.
F5: The shares subject to this option shall vest in equal monthly installments over the next 48 months of continuous service to the Issuer after January 1, 2018.
Stoke Therapeutics, Inc.
Report date March 27, 2024 · Filed June 07, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.17 · Expires 2034-03-26 | Direct | 60,000 |
Reported balance
After 2024-03-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-03-27 · Grant · Acquired 60,000 · Balance 60,000 F1: The option vested or vests as to 1/48 of the total award on April 15, 2024, with 1/48 vesting on each monthly anniversary thereafter, subject to the reporting person's continued service to the issuer through each vesting date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2028-03-15 | Direct | 40,000 |
Reported balance
After 2024-03-27 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-03-27 · Grant · Acquired 40,000 · Balance 40,000 F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F3: The award vests as to 1/4 of the total award annually beginning on March 15, 2025, subject to the reporting person's continued service to the issuer through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vested or vests as to 1/48 of the total award on April 15, 2024, with 1/48 vesting on each monthly anniversary thereafter, subject to the reporting person's continued service to the issuer through each vesting date.
F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement.
F3: The award vests as to 1/4 of the total award annually beginning on March 15, 2025, subject to the reporting person's continued service to the issuer through each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 27, 2024 Filed Jun 7, 2024 20:35 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantRestricted Stock Units · Derivative | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-015995 · form4-06072024_080605.xml · derivative · entry 2 Tulipano Stephen J · CIK 0001360548 · Former CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2028-03-15 F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The award vests as to 1/4 of the total award annually beginning on March 15, 2025, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| March 27, 2024 Filed Jun 7, 2024 20:35 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantEmployee Stock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $14.17 | $0.00 |
DisclosureSEC source: 0001415889-24-015995 · form4-06072024_080605.xml · derivative · entry 1 Tulipano Stephen J · CIK 0001360548 · Former CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2034-03-26 F1 · derivative.exercise_date: The option vested or vests as to 1/48 of the total award on April 15, 2024, with 1/48 vesting on each monthly anniversary thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| March 19, 2024 Filed Mar 20, 2024 00:36 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 4,116 | $6.10 | $25,101.84 |
DisclosureSEC source: 0001415889-24-008690 · form4-03202024_120350.xml · nonDerivative · entry 2 Tulipano Stephen J · CIK 0001360548 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,746 F1 · kind: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.94 to $6.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 15, 2024 Filed Mar 20, 2024 00:36 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionRestricted Stock Units · Derivative | 13,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-008690 · form4-03202024_120350.xml · derivative · entry 3 Tulipano Stephen J · CIK 0001360548 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,300 Underlying: Common Stock · 13,100 shares Expires 2027-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement. F4 · derivative.exercise_date: The award vested or vests as to 1/4th of the total shares annually beginning March 15, 2024, subject to the reporting person's continued service to the Issuer through each vesting date. Read SEC document |
| March 15, 2024 Filed Mar 20, 2024 00:36 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 13,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-008690 · form4-03202024_120350.xml · nonDerivative · entry 1 Tulipano Stephen J · CIK 0001360548 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,862 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 01, 2023 Filed Dec 5, 2023 21:20 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantRestricted Stock Unit (RSU) · Derivative | 60,773 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-057410 · doc4.xml · derivative · entry 4 Tulipano Stephen J · CIK 0001360548 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,773 Underlying: Common Stock · 60,773 shares Expires 2025-12-01 F7 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. F8 · derivative.exercise_date: 48,792 restricted stock units will vest on December 1, 2024 and 11,981 will vest on December 1, 2025, subject to the reporting person's continued service to the Issuer on each such date. Read SEC document |
| December 01, 2023 Filed Dec 5, 2023 21:20 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 107,400 | Not disclosed Strike: $20.34 | Not disclosed |
DisclosureSEC source: 0001209191-23-057410 · doc4.xml · derivative · entry 3 Tulipano Stephen J · CIK 0001360548 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 107,400 shares Expires 2032-03-14 F6 · price: On December 1, 2023, the Issuer cancelled, pursuant to the Issuer's option exchange program, options to purchase 107,400 shares of Common Stock of the Issuer and in exchange issued to the reporting person 33,561 restricted stock units. F5 · derivative.exercise_date: The canceled option vested as to 1/48th of the total award on April 15, 2022 and provided for 1/48th of the total award to vest monthly thereafter, subject to the reporting person's continued service to the Issuer through each vesting date. Read SEC document |
| December 01, 2023 Filed Dec 5, 2023 21:20 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 65,600 | Not disclosed Strike: $60.00 | Not disclosed |
DisclosureSEC source: 0001209191-23-057410 · doc4.xml · derivative · entry 2 Tulipano Stephen J · CIK 0001360548 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 65,600 shares Expires 2031-03-01 F4 · price: On December 1, 2023, the Issuer cancelled, pursuant to the Issuer's option exchange program, options to purchase 65,600 shares of Common Stock of the Issuer and in exchange issued to the reporting person 8,463 restricted stock units. F3 · derivative.exercise_date: The canceled option vested as to 1/48th of the total award on April 2, 2021 and provided for 1/48th of the total award to vest monthly thereafter, subject to the reporting person's continued service to the Issuer through each vesting date. Read SEC document |
| December 01, 2023 Filed Dec 5, 2023 21:20 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 60,000 | Not disclosed Strike: $20.25 | Not disclosed |
DisclosureSEC source: 0001209191-23-057410 · doc4.xml · derivative · entry 1 Tulipano Stephen J · CIK 0001360548 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 60,000 shares Expires 2030-03-24 F2 · price: On December 1, 2023, the Issuer cancelled, pursuant to the Issuer's option exchange program, options to purchase 60,000 shares of Common Stock of the Issuer and in exchange issued to the reporting person 18,749 restricted stock units. F1 · derivative.exercise_date: The canceled option vested as to 1/48th of the total award on April 25, 2020 and provided for 1/48th of the total award to vest monthly thereafter, subject to the reporting person's continued service to the Issuer through each vesting date. Read SEC document |
| March 15, 2023 Filed Mar 17, 2023 20:36 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantRestricted Stock Unit (RSU) · Derivative | 52,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-019669 · doc4.xml · derivative · entry 2 Tulipano Stephen J · CIK 0001360548 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,400 Underlying: Common Stock · 52,400 shares Expires 2027-03-15 F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs vest as to 1/4th of the total shares annually beginning March 15, 2024, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| March 15, 2023 Filed Mar 17, 2023 20:36 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantEmployee Stock Option (Right to Buy) · Derivative | 78,600 | $0.00 Strike: $9.15 | $0.00 |
DisclosureSEC source: 0001209191-23-019669 · doc4.xml · derivative · entry 1 Tulipano Stephen J · CIK 0001360548 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,600 Underlying: Common Stock · 78,600 shares Expires 2033-03-14 F1 · derivative.exercise_date: The option vests as to 1/48th of the total shares on April 15, 2023 and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| December 07, 2022 Filed Dec 9, 2022 22:13 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantEmployee Stock Option (Right to Buy) · Derivative | 62,000 | $0.00 Strike: $7.07 | $0.00 |
DisclosureSEC source: 0001209191-22-060548 · doc4.xml · derivative · entry 1 Tulipano Stephen J · CIK 0001360548 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,000 Underlying: Common Stock · 62,000 shares Expires 2032-12-06 F1 · derivative.exercise_date: The option vests as to 1/48th of the total shares on January 7, 2023 and then 1/48th of the total shares vest monthly thereafter, subject to reporting person's continued service to the issuer through each vesting date. Read SEC document |
| June 02, 2022 Filed Jun 3, 2022 21:00 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 11,160 | $0.00 Strike: $4.48 | $0.00 |
DisclosureSEC source: 0001209191-22-034170 · doc4.xml · derivative · entry 2 Tulipano Stephen J · CIK 0001360548 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,837 Underlying: Common Stock · 11,160 shares Expires 2029-03-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option vested as to 1/4th of the total shares on March 15, 2020, and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| June 02, 2022 Filed Jun 3, 2022 21:00 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 11,160 | $4.48 | $49,996.80 |
DisclosureSEC source: 0001209191-22-034170 · doc4.xml · nonDerivative · entry 1 Tulipano Stephen J · CIK 0001360548 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,762 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 15, 2022 Filed Mar 17, 2022 21:17 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantEmployee Stock Option (Right to Buy) · Derivative | 107,400 | $0.00 Strike: $20.34 | $0.00 |
DisclosureSEC source: 0001209191-22-019687 · doc4.xml · derivative · entry 1 Tulipano Stephen J · CIK 0001360548 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,400 Underlying: Common Stock · 107,400 shares Expires 2032-03-14 F1 · derivative.exercise_date: The option vests as to 1/48th of the total shares on April 15, 2022 and then 1/48th of the total shares vest monthly thereafter, subject to reporting person's continued service to the issuer through each vesting date. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 22:04 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantEmployee Stock Option (Right to Buy) · Derivative | 65,600 | $0.00 Strike: $60.00 | $0.00 |
DisclosureSEC source: 0001209191-21-017878 · doc4.xml · derivative · entry 1 Tulipano Stephen J · CIK 0001360548 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,600 Underlying: Common Stock · 65,600 shares Expires 2031-03-01 F1 · derivative.exercise_date: The option vests as to 1/48th of the total shares on April 2, 2021 and then 1/48th of the total shares vest monthly thereafter, subject to reporting person's continued service to the issuer through each vesting date. Read SEC document |
| February 23, 2021 Filed Feb 24, 2021 22:15 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $4.48 | $0.00 |
DisclosureSEC source: 0001209191-21-013897 · doc4.xml · derivative · entry 8 Tulipano Stephen J · CIK 0001360548 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,997 Underlying: Common Stock · 5,000 shares Expires 2029-03-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vested as to 1/4th of the total shares on March 15, 2020, and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| February 23, 2021 Filed Feb 24, 2021 22:15 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 5,000 | $58.60 | $292,991.50 |
DisclosureSEC source: 0001209191-21-013897 · doc4.xml · nonDerivative · entry 6 Tulipano Stephen J · CIK 0001360548 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 602 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| February 23, 2021 Filed Feb 24, 2021 22:15 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 5,000 | $4.48 | $22,400.00 |
DisclosureSEC source: 0001209191-21-013897 · doc4.xml · nonDerivative · entry 5 Tulipano Stephen J · CIK 0001360548 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,602 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 22:15 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $4.48 | $0.00 |
DisclosureSEC source: 0001209191-21-013897 · doc4.xml · derivative · entry 7 Tulipano Stephen J · CIK 0001360548 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,997 Underlying: Common Stock · 25,000 shares Expires 2029-03-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vested as to 1/4th of the total shares on March 15, 2020, and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 22:15 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 102 | $60.00 | $6,120.00 |
DisclosureSEC source: 0001209191-21-013897 · doc4.xml · nonDerivative · entry 4 Tulipano Stephen J · CIK 0001360548 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 602 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 22:15 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 9,696 | $59.29 | $574,841.90 |
DisclosureSEC source: 0001209191-21-013897 · doc4.xml · nonDerivative · entry 3 Tulipano Stephen J · CIK 0001360548 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 704 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.00 to $59.96 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 22:15 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 15,202 | $58.67 | $891,942.39 |
DisclosureSEC source: 0001209191-21-013897 · doc4.xml · nonDerivative · entry 2 Tulipano Stephen J · CIK 0001360548 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,400 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.00 to $58.99 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 22:15 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 25,000 | $4.48 | $112,000.00 |
DisclosureSEC source: 0001209191-21-013897 · doc4.xml · nonDerivative · entry 1 Tulipano Stephen J · CIK 0001360548 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,602 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 04, 2020 Filed Nov 4, 2020 22:31 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 33,268 | $0.00 Strike: $4.48 | $0.00 |
DisclosureSEC source: 0001209191-20-056953 · doc4.xml · derivative · entry 13 Tulipano Stephen J · CIK 0001360548 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,997 Underlying: Common Stock · 33,268 shares Expires 2029-03-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: The option vested as to 1/4th of the total shares on March 15, 2020, and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| November 04, 2020 Filed Nov 4, 2020 22:31 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 5,216 | $41.97 | $218,909.78 |
DisclosureSEC source: 0001209191-20-056953 · doc4.xml · nonDerivative · entry 10 Tulipano Stephen J · CIK 0001360548 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 602 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F8 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.81 to $42.19 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 04, 2020 Filed Nov 4, 2020 22:31 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 11,111 | $41.42 | $460,214.29 |
DisclosureSEC source: 0001209191-20-056953 · doc4.xml · nonDerivative · entry 9 Tulipano Stephen J · CIK 0001360548 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,818 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F7 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.78 to $41.74 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 04, 2020 Filed Nov 4, 2020 22:31 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 16,941 | $40.03 | $678,085.55 |
DisclosureSEC source: 0001209191-20-056953 · doc4.xml · nonDerivative · entry 8 Tulipano Stephen J · CIK 0001360548 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,929 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.76 to $40.73 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 04, 2020 Filed Nov 4, 2020 22:31 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 33,268 | $4.48 | $149,040.64 |
DisclosureSEC source: 0001209191-20-056953 · doc4.xml · nonDerivative · entry 7 Tulipano Stephen J · CIK 0001360548 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,870 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 03, 2020 Filed Nov 4, 2020 22:31 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 1,732 | $0.00 Strike: $4.48 | $0.00 |
DisclosureSEC source: 0001209191-20-056953 · doc4.xml · derivative · entry 12 Tulipano Stephen J · CIK 0001360548 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 243,265 Underlying: Common Stock · 1,732 shares Expires 2029-03-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: The option vested as to 1/4th of the total shares on March 15, 2020, and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| November 03, 2020 Filed Nov 4, 2020 22:31 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 1,732 | $39.84 | $68,997.51 |
DisclosureSEC source: 0001209191-20-056953 · doc4.xml · nonDerivative · entry 6 Tulipano Stephen J · CIK 0001360548 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 602 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.805 to $39.90 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 03, 2020 Filed Nov 4, 2020 22:31 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 1,732 | $4.48 | $7,759.36 |
DisclosureSEC source: 0001209191-20-056953 · doc4.xml · nonDerivative · entry 5 Tulipano Stephen J · CIK 0001360548 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,334 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 22:31 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $4.48 | $0.00 |
DisclosureSEC source: 0001209191-20-056953 · doc4.xml · derivative · entry 11 Tulipano Stephen J · CIK 0001360548 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244,997 Underlying: Common Stock · 35,000 shares Expires 2029-03-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: The option vested as to 1/4th of the total shares on March 15, 2020, and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 22:31 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 400 | $38.44 | $15,374.00 |
DisclosureSEC source: 0001209191-20-056953 · doc4.xml · nonDerivative · entry 4 Tulipano Stephen J · CIK 0001360548 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 602 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 22:31 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 14,445 | $37.86 | $546,909.37 |
DisclosureSEC source: 0001209191-20-056953 · doc4.xml · nonDerivative · entry 3 Tulipano Stephen J · CIK 0001360548 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,002 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.43 to $38.38 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 22:31 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 20,155 | $36.79 | $741,448.03 |
DisclosureSEC source: 0001209191-20-056953 · doc4.xml · nonDerivative · entry 2 Tulipano Stephen J · CIK 0001360548 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,447 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.43 to $37.36 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 22:31 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 35,000 | $4.48 | $156,800.00 |
DisclosureSEC source: 0001209191-20-056953 · doc4.xml · nonDerivative · entry 1 Tulipano Stephen J · CIK 0001360548 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,602 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 602 shares of Common Stock acquired under the issuer's employee stock purchase plan on June 30, 2020. Read SEC document |
| March 25, 2020 Filed Mar 26, 2020 22:07 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantEmployee Stock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $20.25 | $0.00 |
DisclosureSEC source: 0001209191-20-021321 · doc4.xml · derivative · entry 1 Tulipano Stephen J · CIK 0001360548 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2030-03-24 F1 · derivative.exercise_date: The option vests as to 1/48th of the total shares on April 25, 2020 and then 1/48th of the total shares vest monthly thereafter, subject to reporting person's continued service to the issuer through each vesting date. Read SEC document |
| March 06, 2018 Filed Mar 8, 2018 21:38 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantEmployee Stock Option (Right to Buy) · Derivative | 125,670 | $0.00 Strike: $8.60 | $0.00 |
DisclosureSEC source: 0000899243-18-006817 · doc4.xml · derivative · entry 3 Tulipano Stephen J · CIK 0001360548 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,670 Underlying: Common Stock · 125,670 shares Expires 2028-03-05 F5 · derivative.exercise_date: The shares subject to this option shall vest in equal monthly installments over the next 48 months of continuous service to the Issuer after January 1, 2018. Read SEC document |
| December 29, 2017 Filed Mar 8, 2018 21:38 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantCommon Stock | 3,153 | $4.00 | $12,596.24 |
DisclosureSEC source: 0000899243-18-006817 · doc4.xml · nonDerivative · entry 2 Tulipano Stephen J · CIK 0001360548 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,563 F3 · date: Represents the voluntary reporting of 3,153 shares of common stock acquired under the Issuer's ESPP in December 2017. F3 · shares: Represents the voluntary reporting of 3,153 shares of common stock acquired under the Issuer's ESPP in December 2017. F4 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on July 3, 2017. Read SEC document |
| June 30, 2017 Filed Mar 8, 2018 21:38 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantCommon Stock | 2,077 | $3.95 | $8,209.34 |
DisclosureSEC source: 0000899243-18-006817 · doc4.xml · nonDerivative · entry 1 Tulipano Stephen J · CIK 0001360548 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,410 F1 · date: Represents the voluntary reporting of 2,077 shares of common stock acquired under the Issuer's Employee Stock Purchase Plan (ESPP) in June 2017. F1 · shares: Represents the voluntary reporting of 2,077 shares of common stock acquired under the Issuer's Employee Stock Purchase Plan (ESPP) in June 2017. F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on June 30, 2017. Read SEC document |
| March 03, 2017 Filed Mar 7, 2017 22:45 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantEmployee Stock Option (Right to Buy) · Derivative | 220,980 | $0.00 Strike: $5.10 | $0.00 |
DisclosureSEC source: 0000899243-17-006711 · doc4.xml · derivative · entry 1 Tulipano Stephen J · CIK 0001360548 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,980 Underlying: Common Stock · 220,980 shares Expires 2027-03-02 F1 · derivative.exercise_date: The shares subject to this option shall vest in equal monthly installments over the next 48 months of continuous service to the Issuer after January 1, 2017. Read SEC document |
| February 17, 2017 Filed Feb 21, 2017 21:30 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | PurchaseCommon Stock | 3,333 | $4.50 | $14,998.50 |
DisclosureSEC source: 0000899243-17-004750 · doc4.xml · nonDerivative · entry 1 Tulipano Stephen J · CIK 0001360548 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,333 F1 · price: Represents shares of common stock purchased by the Reporting Person in the Issuer's follow-on offering, which closed on February 17, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.